Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO 2023 Highlights
Zanidatamab Demonstrates Efficacy in Refractory HER2-Amplified Biliary Tract Cancer
Emerging Therapies
,
ASCO 2023 Highlights
October 2023, Vol 14, No 5
Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including
HER2
, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers.
Read Article
Updated ASCO Guidelines Reiterate the Importance of Geriatric Assessment in Older Patients With Cancer
Oncology Practice
,
ASCO 2023 Highlights
,
Geriatric Cancer
October 2023, Vol 14, No 5
The American Society of Clinical Oncology has issued an update to its guidelines for the practical assessment and management of vulnerabilities in patients aged ≥65 years receiving systemic cancer treatment.
Read Article
Improving Diversity in Clinical Trials
By
Phoebe Starr
Disparities in Cancer Care
,
ASCO 2023 Highlights
August 2023, Vol 14, No 4
Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials.
Read Article
Partnering With Patients Key to Improving Healthcare Outcomes
By
Phoebe Starr
ASCO 2023 Highlights
August 2023, Vol 14, No 4
Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.”
Read Article
Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer
By
Phoebe Starr
ASCO 2023 Highlights
,
Breast Cancer
August 2023, Vol 14, No 4
Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive,
HER2
-negative, early breast cancer, according to interim results from the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting.
Read Article
Final OS Analysis Confirms Benefit of Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for First-Line Treatment of Cervical Cancer
By
Phoebe Starr
ASCO 2023 Highlights
,
Cervical Cancer
,
Gynecologic Cancer
,
Women's Health
August 2023, Vol 14, No 4
Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.
Read Article
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
By
Phoebe Starr
ASCO 2023 Highlights
,
Myelodysplastic Syndromes
,
Hematologic Malignancies
August 2023, Vol 14, No 4
Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma